Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source.
Robert G HartMukul SharmaHardi MundlScott E KasnerShrikant I BangdiwalaScott D BerkowitzBalakumar SwaminathanPablo LavadosYongjun WangYilong WangAntonio DavalosNikolay ShamalovRobert MikulikLuis CunhaArne LindgrenAntonio ArauzWilfried LangAnna CzlonkowskaJens EcksteinRubens J GagliardiPierre AmarencoSebastian F AmerisoTurgut TatlisumakRoland VeltkampGraeme J HankeyDanilo ToniDaniel BereczkiShinichiro UchiyamaGeorge NtaiosByung-Woo YoonRaf BrounsMatthias EndresKeith W MuirNatan BornsteinSerefnur OzturkMartin J O'DonnellMatthys M De Vries BassonGuillaume PareCalin PaterBodo KirschPatrick SheridanGary PetersJeffrey I WeitzW Frank PeacockAshkan ShoamaneshOscar R BenaventeCampbell JoynerEllison ThemelesStuart J Connollynull nullPublished in: The New England journal of medicine (2018)
Rivaroxaban was not superior to aspirin with regard to the prevention of recurrent stroke after an initial embolic stroke of undetermined source and was associated with a higher risk of bleeding. (Funded by Bayer and Janssen Research and Development; NAVIGATE ESUS ClinicalTrials.gov number, NCT02313909 .).